tesaglitazar + insulin

Tesaglitazar + insulin refers to the **co-administration of tesaglitazar, a dual peroxisome proliferator-activated receptor alpha/gamma (PPARα/γ) agonist, with insulin therapy**. Tesaglitazar acts by activating both PPARα and PPARγ, leading to improved glucose and lipid metabolism and increased insulin sensitivity. Insulin is a peptide hormone that promotes uptake and utilization of glucose. Clinical and preclinical studies have primarily focused on tesaglitazar as monotherapy or combined with sulphonylureas or other agents. Combination use with insulin has theoretical metabolic synergy: tesaglitazar improves insulin sensitivity (reducing insulin resistance), while exogenous insulin controls glycemia. However, **no uniquely developed or marketed product or fixed-dose combination directly named "tesaglitazar + insulin" exists**. Clinical studies evaluating both agents may have investigated them as separate drugs given concurrently rather than a single combined preparation.